Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Prudential PLC — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.67 (market cap $39.89B), while Prudential PLC trades at $28.29 (market cap $34.34B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Prudential PLC pays a 1.89% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PUK | |
|---|---|---|
Market Cap | $39.89B | $34.34B |
Sector | Health | Financials |
52-Week High | $491.22 | $33.61 |
52-Week Low | $278.09 | $24.65 |
Enterprise Value | $38.15B | $35.78B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Prudential Financial (PUK) trades at $28.13, up 1.33% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 9.16, net income margin of 14.52%, and recent earnings beats. Revenue grew to $16.21B in 2024, with net income reaching $2.29B. Analyst consensus is 50% buy, 37.5% hold, and 12.5% sell. Recent news highlights Q2 2026 earnings anticipation and strategic moves in India.
Outlook is positive with robust profitability and valuation appeal, but risks include Japan sales suspension and regulatory scrutiny. The stock offers growth potential from international expansion, supported by solid cash flow and equity performance. Investors should weigh near-term headwinds against long-term strategic positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
